Business Wire

Chappellet Becomes the Only American Winery to Be Named a Relais & Châteaux Preferred Partner


Napa Valley’s acclaimed Chappellet winery ( ) is excited to announce that it has been invited to become a Relais & Châteaux Preferred Partner. With this honor, Chappellet becomes the first American winery to be invited to become a Preferred Partner and joins an exclusive list of some of the world’s top wineries to be named a Relais & Châteaux Partner. Established in 1954, Relais & Châteaux is an association of more than 580 hotels and restaurants around the world operated by independent innkeepers, chefs, and owners who share a passion for excellence and a desire for authenticity in their relationships with their clientele. Preferred Partners are selected based on their shared values with Relais & Châteaux and their ability to provide unique and unforgettable experiences in their signature areas of expertise. “As a multigeneration, family-owned-and-operated winery that shares Relais & Châteaux's values and passion for excellence, we are thrilled to build on our longstanding relationship with Relais & Châteaux as a Preferred Partner,” said Cyril Chappellet, the second-generation president and chairman of Chappellet.

This press release features multimedia. View the full release here:

To view this piece of content from, please give your consent at the top of this page.

View of Chappellet’s renowned estate vineyard on Pritchard Hill. (Photo: Business Wire)

Founded in 1967 by legendary vintners Donn and Molly Chappellet, Chappellet was the second post-Prohibition winery established in the Napa Valley. Inspired by the notion that “Bacchus loves the hills,” the Chappellet family settled on Pritchard Hill in the eastern mountains of Napa Valley, where they became some of the earliest pioneers of high-elevation vineyard planting. Though grapes grown above 1,000 feet represent only approximately 3% of total production in California, mountain-grown wines represent a significant portion of the most iconic and sought-after wines in America. Still independent and family-run today, Chappellet’s mountain-grown Cabernet Sauvignons from Pritchard Hill have earned global renown and are recognized as benchmarks for their region, having received multiple 100-point scores and glowing comparisons to the First Growths of Bordeaux from top wine critics.

“Since 1967, our family’s winery on Pritchard Hill has been dedicated to crafting world-class, mountain-grown Cabernet Sauvignon,” added Cyril Chappellet. “Like each Relais & Châteaux property, we strive for perfection in everything we do, from the meticulous way we organically farm our vineyard to the deep and enduring bonds we forge with our customers. Over the years, we have enjoyed remarkable relationships with many Relais & Châteaux owners and properties in North America. We look forward to building on these strong connections as we grow our presence around the globe.”

Chappellet has been partnering with a number of Relais & Châteaux properties in North America over the past decade, hosting curated weekends for their collectors at prestigious properties that include Triple Creek Ranch in Montana, The Wauwinet in Nantucket, Massachusetts, Planters Inn in Charleston, South Carolina and Auberge du Soleil in Napa Valley, California.

“I have had the pleasure of working with Chappellet at multiple Relais & Châteaux properties for the last 15 years,” said Molly Smith, the general manager of Triple Creek Ranch. “The history, familiarity, and elegance that the winery has carried through to the guests has elevated experiences and memories.”

As a Preferred Partner, Chappellet will be hosting additional special “Collectors’ Weekends” for both Relais & Châteaux members and Chappellet collectors at Relais & Châteaux properties throughout North America in 2023. The winery will also be developing new ways to engage with Relais & Châteaux members and its global association of restaurants and hotels, including vintner dinners, tasting events, wine education experiences, and the expansion of Chappellet’s “Collectors’ Weekends” into Europe and Asia.

In commenting on Chappellet’s new status as a Preferred Partner, David Fink, the proprietor of Relais & Châteaux property L'Auberge Carmel, said, “More than half a century ago, Donn Chappellet left his corporate life in Los Angeles to find one of the most idyllic places to raise a family and become a wine grower. Today, the Chappellet family carries Donn's vision forward and has created some of the most special wines made in California.”

About Chappellet
In 1967, on the advice of legendary winemaker André Tchelistcheff, the Chappellet family settled on the steep slopes of Pritchard Hill© and founded Chappellet, becoming just the second post-Prohibition winery in Napa Valley. As pioneers of high-elevation vineyard planting, Chappellet has earned acclaim for crafting benchmark wines with an emphasis on mountain-grown Cabernet Sauvignons, while establishing Pritchard Hill as one of the world’s great wine regions.

About Relais & Châteaux - A Movement with Meaning
Relais & Châteaux, established in 1954, is an association of 580 unique hotels and restaurants throughout the world, owned and operated by independent entrepreneurs – most often families – who are passionate about their craft and deeply committed to forging warm, lasting relationships with their guests. Relais & Châteaux members protect and promote the wealth and diversity of the world’s culinary and hospitality traditions, to ensure they continue to thrive. They are equally dedicated to preserving local heritage and the environment, as articulated in the association’s Vision presented to UNESCO in November 2014. For more information, visit

To view this piece of content from, please give your consent at the top of this page.

Contact information

Sonia Ginsburg

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

REGiMMUNE Limited Licenses the Rights to Develop and Commercialize RGI-2001 To San Fu Biotech in Major Asian Countries1.4.2023 19:18:00 EEST | Press release

REGiMMUNE Limited (REGiMMUNE), a biotech company focused on creating innovative immunotherapies for immune disorders and cancer, and San Fu Biotech (SFB), a subsidiary of San Fu Chemical Co., Ltd. (4755.TW) have entered a licensing agreement to develop and commercialize RGI-2001 for the prophylaxis of acute Graft-versus-host disease (aGvHD) in major Asian countries. RGI-2001, with the novel mechanism to improve existing treatments, is a potentially first-in-class small molecule drug candidate targeted for preventing aGvHD, a life-threatening complication resulting from allogeneic hematopoietic stem cell transplantation (HSCT). GvHD is a systemic disorder that occurs when the graft's immune cells recognize the host as foreign and attack the recipient’s body cells or organs, and leads to skin rash, liver problems, abdominal pain or cramps, diarrhea, and increased risk for infections. Patients undergoing allogeneic HSCT have a high-risk of developing aGVHD associated with significant morb

AriBio Co., Ltd. to Present Biomarker Data for AR1001 from the Mild to Moderate Alzheimer’s Disease Phase 2 Study at the International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders (AD/PD™ 2023)31.3.2023 19:00:00 EEST | Press release

AriBio Co., Ltd. announced that David Greeley MD, Chief Medical Officer at AriBio, will present biomarker data from the completed phase 2 study in patients with mild to moderate Alzheimer’s disease who were treated with 10mg and 30mg of AR1001. AR1001 is a potent PDE5 inhibitor with preliminary efficacy in cognition, and preclinical effects on neuron apoptosis inhibition, promotion of neurogenesis, increase in neuroplasticity, and stimulation of autophagy to remove toxic proteins. The phase 2 study was a double-blind, randomized, placebo-controlled, multi-center trial to evaluate the safety and preliminary efficacy of AR1001 over 26 and 52 weeks of treatment in patients with mild to moderate Alzheimer’s disease. The trial enrolled 210 patients at 21 research centers in the United States. Plasma collected from patients at baseline, week 26 and week 52 was analyzed by Quantarix using the Simoa HD-X analyzer. Meaningful, statistically significant changes were found over 52 weeks of treatm

KANEKA: “Development of Polymer Synthesis Technology by Microorganisms using CO2 as Direct Raw Material” selected as a NEDO Green Innovation Fund Project”31.3.2023 17:09:00 EEST | Press release

Kaneka Corporation (Headquarters: Minato-ku, Tokyo; President: Minoru Tanaka; hereinafter "Kaneka"), Bacchus Bio innovation Co., Ltd (Headquarters: Kobe-city, Hyogo; President: Mikio Tanji; hereinafter "Bacchus"), JGC Holdings Corporation (Headquarters: Yokohama-city Kanagawa; Chairman and CEO: Masayuki Sato; hereinafter "JGC HD"), and Shimadzu Corporation (Headquarters: Kyoto-city, Kyoto; President: Yasunori Yamamoto; hereinafter "Shimadzu") have announced that the proposal of a joint project, “Development of Polymer Synthesis Technology by microorganisms using CO2 as direct raw material (hereinafter referred to as ‘the Project’)” had been selected by the "Green Innovation Fund Project*1 / Promotion of Carbon Recycling Using CO2 from Biomanufacturing Technology as a Direct Raw Material” as a planned implementation sponsored by the New Energy and Industrial Technology Development Organization (NEDO). This press release features multimedia. View the full release here: https://www.busine

Allianz Appoints Leadership for Allianz Commercial Key Markets31.3.2023 16:11:00 EEST | Press release

As part of the implementation of its ‘Integrated Commercial’ strategy to better serve the full Commercial segment, Allianz Group today announced the leadership for four of its largest Property and Casualty Commercial insurance markets: Australia, France, Germany and the United Kingdom. In each country, the appointed single Commercial lead will represent the integrated Allianz Commercial business and bring to the market Allianz’s full set of solutions for specialty clients, large corporates, and mid-sized companies, simplifying and enhancing the experience of clients and distribution partners. “The appointment of the regional leaders in our core Allianz Commercial markets is an important, concrete step toward realizing our new integrated model, which brings together our Mid Corporate and Large Corporate insurance business for the benefit of our clients and distribution partners,” said Chris Townsend, Member of the Allianz SE Board of Management. Townsend added, “As one face to the marke

Huawei Releases 2022 Annual Report: Steady Operations, Sustainable Survival and Development31.3.2023 12:59:00 EEST | Press release

Huawei released its 2022 Annual Report today. The company reports steady operations throughout 2022, having generated CNY642.3 billion in revenue and CNY35.6 billion in net profits. Huawei continues to strengthen investment in R&D, with an annual expenditure of CNY161.5 billion in 2022, representing 25.1% of the company's annual revenue and bringing its total R&D expenditure over the past 10 years to more than CNY977.3 billion. This press release features multimedia. View the full release here: (Photo: Huawei) "In 2022, a challenging external environment and non-market factors continued to take a toll on Huawei's operations", said Eric Xu, Huawei's Rotating Chairman, at the company's annual report press conference. "In the midst of this storm, we kept racing ahead, doing everything in our power to maintain business continuity and serve our customers. We also went to great lengths to grow the harvest – generating a steady stream

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom